JP2016534023A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534023A5
JP2016534023A5 JP2016515409A JP2016515409A JP2016534023A5 JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5 JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5
Authority
JP
Japan
Prior art keywords
hydroxy
propan
pyrrolidin
oxoacetamide
dioxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515409A
Other languages
English (en)
Japanese (ja)
Other versions
JP6537500B2 (ja
JP2016534023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/056555 external-priority patent/WO2015042397A1/en
Publication of JP2016534023A publication Critical patent/JP2016534023A/ja
Publication of JP2016534023A5 publication Critical patent/JP2016534023A5/ja
Application granted granted Critical
Publication of JP6537500B2 publication Critical patent/JP6537500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515409A 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤 Active JP6537500B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361880752P 2013-09-20 2013-09-20
US61/880,752 2013-09-20
PCT/US2014/056555 WO2015042397A1 (en) 2013-09-20 2014-09-19 Glucosylceramide synthase inhibitors for the treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104161A Division JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016534023A JP2016534023A (ja) 2016-11-04
JP2016534023A5 true JP2016534023A5 (enExample) 2017-11-02
JP6537500B2 JP6537500B2 (ja) 2019-07-03

Family

ID=51794951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Country Status (10)

Country Link
US (2) US10227323B2 (enExample)
EP (2) EP3046920B1 (enExample)
JP (2) JP6537500B2 (enExample)
CN (2) CN110372636B (enExample)
AU (2) AU2014321397C1 (enExample)
CA (1) CA2924545C (enExample)
IL (2) IL244628B (enExample)
MX (1) MX374452B (enExample)
TW (2) TWI690511B (enExample)
WO (1) WO2015042397A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
US11744396B1 (en) * 2015-11-10 2023-09-05 Caffeine Innovations, LLC System, method, and device for agitating coffee grounds
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN107216238A (zh) * 2016-03-21 2017-09-29 湖南师范大学 醇镁法制备4-甲基儿茶酚
WO2018041935A1 (en) * 2016-09-02 2018-03-08 Igm Group B.V. Polycyclic glyoxylates as photoinitiators
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MD3448859T2 (ro) 2017-03-20 2020-03-31 Forma Therapeutics Inc Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
CA3054587A1 (en) 2017-03-28 2018-10-04 Basf Se Pesticidal compounds
UA127604C2 (uk) 2017-12-21 2023-11-01 Басф Се Пестицидні сполуки
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
WO2021020363A1 (ja) * 2019-07-29 2021-02-04 武田薬品工業株式会社 複素環化合物
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
EP4048397B1 (en) * 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
RS65662B1 (sr) * 2019-11-15 2024-07-31 Yuhan Corp Derivati koji imaju 2,3-dihidro-1h-inden ili 2,3-dihidrobenzofuranski deo ili njihovu farmaceutski prihvatljivu so i farmaceutske kompozicije koje ih sadrže
US12338237B2 (en) 2019-11-15 2025-06-24 Yuhan Corporation Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
US20230212123A1 (en) * 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113912544B (zh) * 2021-11-29 2023-03-17 沧州普瑞东方科技有限公司 一种5-溴-1-甲基吲唑的制备方法
EP4573081A1 (en) * 2022-08-18 2025-06-25 Acelink Therapeutics, Inc. Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
CN115433157B (zh) * 2022-11-09 2023-02-07 苏州凯瑞医药科技有限公司 一种依利格鲁司特中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
RO122246B1 (ro) 1999-05-07 2009-03-30 Texas Biotechnology Corporation Derivaţi de acid propionic ce inhibă legarea integrinelor de receptorii acestora, compoziţie farmaceutică ce îi conţine şi utilizare
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
US20020156063A1 (en) 2001-04-06 2002-10-24 Setti Eduardo L. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
JP5038582B2 (ja) 2001-07-16 2012-10-03 ジェンザイム・コーポレーション Udp−グルコース:n−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
JPWO2003057874A1 (ja) 2001-12-28 2005-05-19 住友製薬株式会社 腎疾患の疾患マーカー及びその利用
AU2004220087A1 (en) 2003-03-06 2004-09-23 Seneb Biosciences, Inc. Methods and compositions for the enzymatic synthesis of gangliosides
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
CN101023064B (zh) * 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
ES2565236T3 (es) 2005-01-26 2016-04-01 Allergan, Inc. Amidas del ácido 3-aril-3-hidroxi-2-amino-propiónico, amidas del ácido 3-heteroaril-3-hidroxi-2-amino-propiónico y compuestos relacionados que tienen actividad analgésica y/o inmunoestimuladora
PT2032134E (pt) 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US20100105687A1 (en) 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
US8304447B2 (en) * 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
BRPI0817864A2 (pt) * 2007-10-05 2012-12-25 Genzyme Corp uso de um composto derivado de ceramida
MY167602A (en) 2007-11-01 2018-09-20 Acucela Inc Amine derivatives compounds for treating ophthalmic diseases and disorders
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
EP3078373A1 (en) * 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
BR112012012947B8 (pt) * 2009-11-27 2021-05-25 Genzyme Corp sal de hemitartarato e composição farmacêutica compreendendo o mesmo
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US8961959B2 (en) * 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Similar Documents

Publication Publication Date Title
JP2016534023A5 (enExample)
JP2019182869A5 (enExample)
US10913727B2 (en) Modulators of the integrated stress pathway
JP6385954B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
Peifer et al. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1 H-indole-3yl)-1, 5-dihydro-2 H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors
RU2586974C2 (ru) Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств
US9862716B2 (en) TRKA kinase inhibitors, compositions and methods thereof
US11155557B2 (en) Pyrazolopyrimidine compounds and methods of use thereof
IL303196B1 (en) Heteroaryl substituted pyridines and methods of use
JP2016517878A5 (enExample)
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
TW201718597A (zh) Hpk1抑制劑及其使用方法
JP2010513444A5 (enExample)
JP2020515575A5 (enExample)
BG108013A (bg) Заместени аминопроизводни и методи за използването им
RU2019132212A (ru) Селективные ингибиторы hdac6
ES2342783T3 (es) Aril aciltioureas sustituidas y compuestos relacionados, inhibidores de la replicacion viral.
MX2014013011A (es) Compuesto heterociclico nitrogenado.
JP2017530185A5 (enExample)
JP7744350B2 (ja) 置換ピラゾロ-ピリミジンおよびその使用
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
JP2017519818A5 (enExample)
JP2016535051A5 (enExample)
JP2011510985A5 (enExample)